Mara Goldstein


Cantor Fitzgerald Remains Positive on Celgene Corporation (CELG) Following Collaboration with Juno Therapeutics Inc (JUNO)

Cantor Fitzgerald analyst Mara Goldstein weighed in with a few of her opinions on Celgene Corporation (NASDAQ:CELG) following the company’s $1 billion collaboration with …

Here’s Why Oncothyreon Inc (USA) Shares Are Fully Valued: Cantor

Oncothyreon Inc (USA) (NASDAQ:ONTY) shares have taken off, adding 24.56% to trade at $4.

Cantor Cuts Price Target for NewLink Genetics Corp Following the Continuation of Phase III IMPRESS Trial

In a research report released May 12, Cantor analyst Mara Goldstein reduced the price target of NewLink Genetics Corp (NASDAQ:NLNK) to $44 (from $48), after the …

Cantor Fitzgerald Remains Positive on Array Biopharma Inc Following Promising 3Q:FY15 Results

Cantor Fitzgerald analyst Mara Goldstein released a research report on Array Biopharma Inc (NASDAQ:ARRY) reiterating a Buy rating on the stock and providing a price target …

Cantor Weighs On Celgene Corporation’s 1Q’15 Results

In a research report issued Friday, Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on Celgene Corporation (NASDAQ:CELG) with a price target of …

Cantor Reiterates Buy on Celgene Corporation Ahead of 1Q:15 Update

In a research report issued today, Cantor analyst Mara Goldstein reiterated a Buy rating on Celgene Corporation (NASDAQ:CELG) with a price target of …

Cantor Remains Cautious on Galena Biopharma Inc Following 4Q Earnings

In a research report issued today, Cantor analyst Mara Goldstein maintained a Sell rating on Galena Biopharma Inc (NASDAQ:GALE) with a $2.00 price target, …

Cantor Reiterates Buy Rating On NewLink Genetics Amid 4Q14 Results

Cantor analyst Mara Goldstein reiterated a Buy rating on NewLink Genetics Corp (NASDAQ:NLNK) with a price target of $48, following the company’s fourth quarter …

Cantor Maintains Hold On ImmunoGen Following 2Q:FY15 Results

In a research report sent to investors, Cantor analyst Mara Goldstein reiterated a Hold rating on ImmunoGen (NASDAQ:IMGN) with a $9.00 price target, following …

UPDATE: Cantor Raises Array Biopharma Price Target Following Encorafenib Acquisition

In a research report published Monday, Cantor analyst Mara Goldstein maintained a Buy rating on Array Biopharma (NASDAQ:ARRY) with a $13 price target, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts